Tower Research Capital LLC TRC Buys 15,431 Shares of CEL-SCI Co. (NYSE:CVM)

Tower Research Capital LLC TRC raised its stake in CEL-SCI Co. (NYSE:CVM) by 2,011.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,198 shares of the company’s stock after acquiring an additional 15,431 shares during the period. Tower Research Capital LLC TRC’s holdings in CEL-SCI were worth $44,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Sheets Smith Wealth Management acquired a new stake in shares of CEL-SCI in the fourth quarter valued at $54,000. Black Diamond Financial LLC increased its position in CEL-SCI by 20.5% in the 3rd quarter. Black Diamond Financial LLC now owns 53,000 shares of the company’s stock valued at $66,000 after acquiring an additional 9,000 shares in the last quarter. Vontobel Holding Ltd. bought a new position in shares of CEL-SCI in the fourth quarter worth about $68,000. Lincoln National Corp lifted its position in shares of CEL-SCI by 138.2% during the third quarter. Lincoln National Corp now owns 55,545 shares of the company’s stock worth $69,000 after purchasing an additional 32,225 shares in the last quarter. Finally, Cutter & CO Brokerage Inc. grew its stake in shares of CEL-SCI by 20.5% during the third quarter. Cutter & CO Brokerage Inc. now owns 102,845 shares of the company’s stock valued at $129,000 after purchasing an additional 17,500 shares during the last quarter. 12.08% of the stock is currently owned by institutional investors.

CEL-SCI Stock Performance

Shares of NYSE CVM traded up $0.06 during midday trading on Thursday, hitting $1.48. The stock had a trading volume of 133,299 shares, compared to its average volume of 283,034. The company’s 50-day simple moving average is $1.85 and its 200 day simple moving average is $2.20. CEL-SCI Co. has a fifty-two week low of $1.04 and a fifty-two week high of $3.23. The company has a quick ratio of 0.78, a current ratio of 1.26 and a debt-to-equity ratio of 0.75.

CEL-SCI (NYSE:CVM) last released its earnings results on Wednesday, February 14th. The company reported ($0.14) EPS for the quarter. Equities analysts anticipate that CEL-SCI Co. will post -0.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com cut CEL-SCI from a “hold” rating to a “sell” rating in a research note on Friday, March 15th.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.